The Road to Recovery,    We are open.    We are clean.    We are ready.   Learn More!
School of Nursing | HNH Fitness | Villa Marie Claire | Simulation Learning | About Holy Name | Careers | Ways to Give

We are open.
We are clean.
We are ready.

Holy Name Medical Center is happy to announce that we have begun our return to normal operations. You may wonder, Is the hospital safe? Yes. We are ready. Ready to partner with you and your family on all your healthcare needs.

Holy Name is the first hospital in North Jersey to complete a rigorous, deep cleaning of our 450,000 square feet of clinical and non-clinical space. We started with manual disinfection, then applied electrostatic sanitizing mist, and finally, blasted UV-C light to kill more than 30 types of pathogens — including Covid-19.

Learn How Holy Name Became COVID-19 Clean

Now is a good time to think about your overall health and wellness. How can Holy Name help you?

View our services A-Z

Medical Care


Patients & Visitors




About Holy Name Medical Center About Holy Name Medical Center

Key Phone Numbers

  • Medical Center Operator

  • 201-833-3000

  • Physician Referral Service

  • 877-HOLY-NAME (465-9626)

  • Patient Information

  • 201-833-3300

  • Foundation (Donations)

  • 201-833-3187

  • Human Resources

  • 201-833-7040

  • Medical Staff Office

  • 201-833-3352

View All Department Contact Numbers

For general questions or comments, email info@holyname.org


For More Information:

201-837-0727
Donate Now
Support the MS Center at Holy Name

MS Drug - Ocrevus

Ocrevus (ocrelizumab) has received approval by the Food and Drug Administration (FDA) for treating relapsing MS and primary progressive MS. Eligible patients have been given ocrevus at the MS Center at Holy Name through clinical trials but it will also be available to other MS patients, probably within a few months. Ocrevus is an intravenous medication that is administered three times yearly.

In clinical trials, three markers were used to determine the medication's effectiveness - decrease in relapse rates, reduced MRI activity and a slowing of disability progression. The FDA's approval is based on these trials showing ocrevus significantly reduced disease progression in patients with primary progressive multiple sclerosis by 24 percent, sustained for at least 12 weeks. Studies also found that ocrevus helped reduce the annual relapse rate in patients with relapsing MS by nearly 50 percent over a 2-year period.

Clinical trials involving ocrevus at Holy Name will continue and patients will see no disruption in their participation. Other patients with both relapsing and progressive types of MS who are felt to be appropriate candidates for the drug will be notified by staff members to come in for a consultation. Please keep in mind the drug will not be immediately available for infusion and insurance approval will also take time.